Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-11-25Clinical Trial Update: Effect of Mechanical Loading With PTH on Cortical Bone [Phase 4]
Phase 4 trial investigating the effect of mechanical loading with parathyroid hormone on cortical bone in postmenopausal osteoporosis has be…
-
CLINICAL_TRIALS withdrawal · 2025-05-25Clinical Trial Update: Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis [NA]
A clinical trial evaluating a novel resistance exercise for individuals with osteoporosis/osteopenia has been withdrawn from the registry.
-
EMA withdrawal · 2020-05-19EMA Withdrawn: Osseor (strontium ranelate) — Les Laboratoires Servier
The EMA has withdrawn Osseor (strontium ranelate) from the market.
-
EMA withdrawal · 2020-05-15EMA Withdrawn: Protelos (strontium ranelate) — Les Laboratoires Servier
The EMA withdrew Protelos (strontium ranelate) from the market for osteoporosis, postmenopausal indications.
-
CLINICAL_TRIALS withdrawal · 2016-11-02Clinical Trial Update: A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This clinical trial update notes that the quarterly intravenous ibandronate (Bonviva) study in women with postmenopausal osteoporosis is no …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-08-27Clinical Trial Update: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) [Phase 3]
The Phase 3 trial MK-0822-050 evaluating odanacatib in postmenopausal osteoporosis previously treated with alendronate has been withdrawn.
-
EMA withdrawal · 2014-07-02EMA Withdrawn: Preotact (parathyroid hormone (rDNA)) — NPS Pharma Holdings Limited
EMA has withdrawn Preotact (parathyroid hormone rDNA) from the market.
-
EMA withdrawal · 2013-05-13EMA Withdrawn: Bondenza (previously Ibandronic Acid Roche) (ibandronic acid) — Roche Registration Ltd.
The EMA indicates that Bondenza (ibandronic acid) has been withdrawn from the market.
-
EMA withdrawal · 2012-06-21EMA Lapsed: Fablyn (Lasofoxifene tartrate) — Dr. Friedrich Eberth Arzneimittel GmbH
EMA indicates the marketing authorization for Fablyn (lasofoxifene tartrate) has lapsed, primarily in the osteoporosis/postmenopausal settin…